Abstract. A 77-year-old man was admitted to the hospital with a thyroid nodule. The levels of serum tumor-associated carbohydrate antigens (CA 50, and thyroglobulin (HTG) were markedly increased. We performed total thyroidectomy and right neck lymph node dissection. After treatment, the serum CA 50, CA 19-9 and HTG levels were markedly decreased. Histological examination of the thyroid tumor showed papillary adenocarcinoma and the dissected neck lymph nodes contained metastatic adenocarcinoma.
CARBOHYDRATE antigen 50 (CA 50) and carbohydrate antigen 19-9 (CA 19-9) are antigens related to cancer [1, 2] , and are regarded as very useful markers for malignant tumors of the pancreaticobiliary system. Very little investigation has been performed concerning their usefulness as tumor markers for thyroid cancer. Recently, the authors have seen a patient with papillary adenocarcinoma of the thyroid who showed very high serum CA 50 and CA 19-9 levels as well as the expression of CA 50 and CA 19-9 by the tumor tissue. Therefore, to investigate the usefulness of CA 50 and CA 19-9 as tumor markers in papillary adenocarcinoma of the thyroid, the serum levels of CA 50 and CA 19-9 and the expression of CA 50 in the thyroid tissues were studied in other subjects.
Case Report
A 77-year-old male noticed a mass in the right anterior cervical region about July, 1989, and was admitted to our hospital for investigation in September of the same year.
On physical examination, the height was 161 cm, and the weight was 55kg. shows the staining of formalin-fixed and paraffinembedded tissue by an indirect enzyme-labelled antibody method with monoclonal antibody to CA 50. In the thyroid tumor, the cell membranes were largely stained along with a part of the cytoplasm (Fig. 1 a) , but there was no staining in the normal thyroid tissue (Fig. 1b) . The cell membranes and cytoplasm of cancer cells in the metastatic lymph nodes were also stained (Fig. lc) . Fig. 2 shows staining of the same tissue by an indirect enzymelabelled antibody method with monoclonal antibody to CA 19-9. In both the tumor tissue of the * It is reported that generally the serum CA 19 -9 level obtained by EIA is lower than by RIA, but when the antigen level is very high the level measured by RIA is occasionally lower than by EIA. thyroid and the metastatic lymph nodes, positive cancer cells were less common than when CA 50 expression was assessed. The expression of the other tumor markers in the thyroid tissue was not assessed.
After the operation, the serum CA 50 level was 82U/ml (EIA), the CA 19-9 level was 282U/ml (RIA) and 523.7U/ml (EIA), and the HTG level was 237.5ng/ml, all of which were markedly decreased, but were not within the normal range. 131I scintigraphy revealed an accumulation in the cervical region suggesting a residual carcinoma. We administrated a 1.1 GBq dose of 1311. However, these levels started to increase again 5 months after the operation, and 99mTc scintigraphy revealed accumulation in the sacroiliac joint suggesting a recurrence (Fig. 3) .
Materials and Methods
The subjects were 94 patients with papillary adenocarcinoma of the thyroid and 50 patients with benign nodules of the thyorid (all diagnosed at operation), as well as 98 healthy individuals (total: 242 subjects). The patient reported above was excluded.
Serum CA 50 levels were measured with a DELFIA kit (Pharmacia Diagnostics, Sweden) and an EIA kit (Mitsui Pharmaceuticals Inc., Japan), while the serum CA 19-9 level was assessed with an RIA kit (Centocor Inc., U.S.A.). The normal ranges of these tumor markers were described previously. The expression of CA 50 in the tissues was determined by an indirect enzyme-labelled antibody method with monoclonal antibody to CA 50 after formalin fixation and paraffin embedding. Data were subjected to the t-test and x2 test to determine significant differences (P<0.05).
Results
The positive rates for CA 50 (DELFIA), CA 50 (EIA), and CA 19-9 (RIA) were 4.3%, 1.1% and 2.1%, respectively, in papillary adenocarcinoma. These levels were not significantly higher than in the normal individuals or the patients with benign nodules (Table 3) .
The relationship between the carcinomatous diameter and the CA 50 (DELFIA), CA 50 (EIA), and CA 19-9 (RIA) serum levels in papillary adenocarcinoma was assessed. For CA 50 by DELFIA (r=0.237) and for CA 19-9 by RIA (r=0.297), a significant positive correlation was noted (Fig. 4) .
Concerning the expression of CA 50 in thyroid tissue, it was positive in 12 out of 13 cases of papillary adenocarcinoma.
No correlation was noted between the serum CA 50 level and the degree of immuno-staining.
Discussion
Serum CA 50 and CA 19-9 levels show positive rates of 60-90% in malignant tumors of the pancreaticobiliary system [4, 5] . For cancer of the thyroid, there are no reports on serum CA 50 levels, while serum CA 19-9 levels have only been reported by Nomizu et al. [6] and by Hashimoto et al. [7] . They found that they were positive in 5.3-11.3% of the patients with thyroid cancer and that the values were less than 100 U/ml. In the patient reported here, serum CA 50 and CA 19-9 levels were markedly raised to more than 400 U/ml, decreased markedly after excision of the tumor, and rose again with tumor recurrence. A study of serum CA 50 and CA 19-9 levels in other 94 cases of papillary adenocarcinoma of the thyroid showed a positive rate of 1.1-4.3% and 2.1%, and not significantly higher than those in normal subjects or in benign nodules. But in patients with papillary adenocarcinoma of the thyroid, both CA 50 and CA 19-9 there were significantly higher serum levels as the cancer enlarged.
Concerning the expression of CA 50 and CA 19-9 in the thyroid gland, Vierbuchen et al. [8] reported that these antigens did not stain normal thyroid tissue and thyroid adenomas, while CA 50 was positive in 15 out of 25 cases of follicular adenocarcinoma and CA 19-9 in six cases. Also, among 52 cases of papillary adenocarcinoma, CA 50 was detected in 48 cases and CA 19-9 in 25 cases. The authors' patient showed abnormally high serum CA 50 and CA 19-9 levels, and both CA 50 and CA 19-9 were expressed by carcinoma cells in the thyroid gland, but CA 50 staining was more common and more intense. CA 50 was also positive in 12 out of 13 cases of papillary adenocarcinoma.
Since CA 50 has a higher serum positive rate than CA 19-9 as well as more positive cells and more intense staining, the following is considered. Sialyl transferase (a carbohydrate transferase) first increases abnormally during malignant transformation to form CA 50. Then fucosyl transferase, which is a Lewis a synthetase governed by the gene of the Lewis a blood type, acts to form CA 19-9. Some of these antigens then enter the blood. But CA 19-9 is not formed in patients with the Lewis a-and b-blood types (5-10% of the Japanese population).
A patient with papillary adenocarcinoma of the thyroid was seen in which markedly high serum CA 50 and CA 19-9 levels and the expression of both antigens in the tumor tissue were noted. The positive rates for these serum levels in other patients with papillary adenocarcinoma were not significantly higher than in patients with benign nodules or in normal subjects. These results suggest that serum levels of CA 50 and CA 19-9 might not become useful markers for the diagnosis of thyroid carcinoma, but might be useful markers for monitoring the growth or recurrence of papillary adenocarcinoma of the thyroid in patients with high serum levels of CA 50 and CA 19-9.
